Hyperthermic isolated limb perfusion: Evolving concepts in the treatment of extremity soft tissue sarcomas

Current Opinion in Orthopaedics

Volumn 17, Issue 6, 2006, Pages 558-562

  Lewis, James M ^a   Sanders, Geremy ^a   Reintgen, Douglas ^a   Letson, G Douglas ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

External beam radiation; Hyperthermic isolated limb perfusion; Melphalan; Quality of life; Soft tissue sarcoma; Tumor necrosis factor

Indexed keywords

ANALGESIC AGENT; DOXORUBICIN; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

CANCER GROWTH; CARDIOTOXICITY; CLINICAL TRIAL; DOSE RESPONSE; EDEMA; ERYTHEMA; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HYPERTHERMIC THERAPY; LIMB PERFUSION; LIMB SALVAGE; LIMB TUMOR; NAUSEA; NEURALGIA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SOFT TISSUE SARCOMA; SYSTEMIC DISEASE; TISSUE INJURY; TREATMENT RESPONSE; VOMITING;

EID: 33750549063     PISSN: 10419918     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bco.0000247367.49201.6b     Document Type: Review

References (31)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Can J Clin 2005; 56:106-130.
2. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluation of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982; 196:305-315.
3. Willard WC, Hajdu SI, Casper ES, Brennan MS. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 1992; 215:269-275.
4. Creech O Jr, Krementz ET, Ryan RF, Winbald JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148:616-632.
5. Eggermont AM. Treatment of melanoma in-transit metastases confined to the limb. Cancer Surv 1996; 26:335-349.
6. Klaase JM, Kroon BB, Van Geel AN, et al. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994; 115:39-45.
7. Lejeune FJ, Deloof T, Ewalenko P, et al. Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolated perfusion of the limbs with melphalan: recent results. Cancer Res 1983; 86:268-276.
8. Minor DR, Allen RE, Alberts D, et al. A clinical and pharmaco-kinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 1985; 55:2638-2644.
9. Krementz ET, Carter RD, Sutherland CM, Hutton I. Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg 1977; 185:555-564.
10. Hoekstra HJ, Schraffordt Koops H, Molenaar WM, Oldhoff J. Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities. Cancer 1987; 60:1703-1707.
11. Kim CJ, Puleo C, Letson GD, Reintgen D. Hyperthermic isolated limb perfusion for extremity sarcomas. Cancer Control 2001; 8:269-273.
12. Eggermont AM, De Wilt JH, Ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003; 4:429-437.
13. Wieberdink J, Benckhuysen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18:905-910.
14. Grunhagen DJ, de Wilt JH, Graveland WJ, et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-α and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006; 106:1776-1784. This paper collectively highlights the overall outcomes of ILP in a large series.
15. Grunhagen DJ, Brunstein F, Graveland WJ, et al. Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg. Ann Surg Oncol 2005; 12:1-7.
16. Bonvalot S, Laplanche A, Lejeune F, et al. Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol 2005; 16:1061-1068. This randomized study evaluates the role of decreasing TNF-α dose demonstrating similar efficacy and lower complication rates with low-dose TNF-α.
17. Rossi CR, Mocellin S, Pilati P, et al. Hyperthermic isolated perfusion with low-dose tumor necrosis factor a and doxorubicin for the treatment of limb-threatening soft tissue sarcomas. Ann Surg Oncol 2005; 12:1-8.
18. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13:1537-1545.
19. Grunhagen DJ, De Wilt JH, Van Geel AN, et al. TNF dose reduction in isolated limb perfusion. Eur J Surg Oncol 2005; 31:1011-1019.
20. Thijssens KM, Van Ginkel RJ, Pras E, et al. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy. Ann Surg Oncol 2006; 13:518-524. This study documents the role of adjuvant radiotherapy in post-ILP/resection patients. Notes value of external beam radiation in R0 resected extremity STS patients.
21. Lans TE, Grunhagen DJ, De Wilt JH, et al. Isolated limb perfusions with TNF and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs. Ann Surg Oncol 2005; 12:406-411.
22. Zagars GK, Ballo MT, Pisters PW, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservative surgery and radiation therapy: an analysis of 225 patients. Cancer 2003; 97:2530-2543.
23. Grunhagen DJ, De Wilt JH, Graveland WJ, et al. The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer 2006; 106:156-162.
24. Thijssens KMJ, Hoekstra-Weebers JEHM, Van Ginkel RJ, Hoekstra H. Quality of life after hyperthermic isolated limb perfusion for locally advanced extremity soft tissue sarcoma. Ann Surg Oncol 2006; 13:864-871. Exciting review of long-term quality of life and satisfaction after ILP.
25. Cordova MJ, Andrykowski MA, Kenady DE, et al. Frequency and correlates of posttraumatic-stress-disorder-like symptoms after treatment for breast cancer. Consult Clin Psychol 1995; 63:981-986.
26. Green BL, Rowland JH, Krunpnick JL, et al. Prevalence of posttraumatic stress disorder in women with breast cancer. Psychosomatics 1998; 39:102-111.
27. Widows MR, Jacobson PB, Fields KK. Relation of psychological vulnerability factors to posttraumatic stress disorder symptomatology in bone marrow transplant recipients. Psychosom Med 2000; 62:873-882.
28. Hampton MR, Frombach I. Women's experience of traumatic stress in cancer treatment. Health Care Women Int 2000; 21:67-76.
29. Eilber FC, Brennan MF, Riedel E, et al. Prognostic factors for survival in patients with locally recurrent extremity soft tissue sarcoma. Ann Surg Oncol 2005; 12:228-236.
30. Coindre J-M, Terrier P, Bui NB, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma: a study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 1996; 14:869-877.
31. Fiore M, Casali PG, Miceli R, et al. Prognostic effect of re-excision in adult soft tissue sarcoma of the extremity. Ann Surg Oncol 2006; 13:110-117.